Bernard Schneider

Publications associées (114)

À propos
Confidentialité
Mentions légales

Graph Chatbot

Cerebellar dysfunction in frontotemporal dementia: intra-cerebellar pathology and cerebellar network degeneration

Bernard Schneider

Background: Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) share overlapping clinical, genetic, and neuroimaging features; a spectrum of conditions commonly referred to as the ALS-FTD continuum. The majority of imaging studies focus ...

2025

Optogenetic modulation of peripheral nociceptive neurons with biocompatible optoelectronic implants

Stéphanie Lacour, Bernard Schneider, Ivan Furfaro, Frédéric Pierre Gérald Michoud, Valentina Marie Paggi

Hyperexcitability of peripheral sensory neurons plays a critical role in the development and maintenance of chronic pain. Pharmacological analgesics used in clinics reduce neuronal activity. They often come with non‐negligible side effects. Optogenetic app ...

Wiley2025

Single-cell and spatial atlases of spinal cord injury in the Tabulae Paralytica

Grégoire Courtine, Bernard Schneider, Jocelyne Bloch, Quentin Barraud, Nicholas David James, Matthieu Pierre Gautier, Claudia Kathe, Thomas Haynes Hutson, Michael Alexander Skinnider, Michael V. Sofroniew

Here, we introduce the Tabulae Paralytica—a compilation of four atlases of spinal cord injury (SCI) comprising a single-nucleus transcriptome atlas of half a million cells, a multiome atlas pairing transcriptomic and epigenomic measurements within the same ...

Springer Science and Business Media LLC2024

Liver SMN restoration rescues the Smn2B/- mouse model of spinal muscular atrophy

Bernard Schneider

Background: The liver is a key metabolic organ, acting as a hub to metabolically connect various tissues. Spinal muscular atrophy (SMA) is a neuromuscular disorder whereby patients have an increased susceptibility to developing dyslipidaemia and liver stea ...

2024

Interactions of VMAT2 with CDCrel-1 and Parkin in Methamphetamine Neurotoxicity

Bernard Schneider

In recent years, methamphetamine (METH) misuse in the US has been rapidly increasing, and there is no FDA-approved pharmacotherapy for METH use disorder (MUD). In addition to being dependent on the drug, people with MUD develop a variety of neurological pr ...

2024

Production and Purification of Adeno-Associated Viral Vectors (AAVs) Using Orbitally Shaken HEK293 Cells

Bernard Schneider, Pamela Solange Valdés Undurraga

Humana Press2024

Neurotrauma treatment

Grégoire Courtine, Bernard Schneider, Jordan Squair, Mark Andrew Anderson

The invention provides pharmaceutical compositions, combinations and vectors, such as expression vectors, as well as use thereof in a method for central nervous system repair after neurotrauma, such as spinal cord injury (SCI) or stroke and in a method for ...

2024

TNFα prevents FGF4-mediated rescue of astrocyte dysfunction and reactivity in human ALS models

Bernard Schneider

Astrocytes play a crucial role in the onset and progression of amyotrophic lateral sclerosis (ALS), a fatal disorder marked by the degeneration of motor neurons (MNs) in the central nervous system. Although astrocytes in ALS are known to be toxic to MNs, t ...

Elsevier BV2024

Mitofusin-2 in nucleus accumbens D2-MSNs regulates social dominance and neuronal function

Bernard Schneider, Maria del Carmen Sandi Perez, Jocelin Grosse, Olivia Zanoletti, Elias Georges Gebara, Marie-Isabelle Guillot de Suduiraut, Simone Astori, Alessandro Chioino, Sriparna Ghosal, Eva Ramos Fernandez

The nucleus accumbens (NAc) is a brain hub regulating motivated behaviors, including social competitiveness. Mitochondrial function in the NAc links anxiety with social competitiveness, and the mitochondrial fusion protein mitofusin 2 (Mfn2) in NAc neurons ...

2023

Long term peripheral AAV9-SMN gene therapy promotes survival in a mouse model of spinal muscular atrophy

Bernard Schneider

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease characterized by motor neuron loss and skeletal muscle atrophy. SMA is caused by the loss of the SMN1 gene and low SMN protein levels. Current SMA therapies work by increasing SM ...

Oxford University Press2023

Page 1 sur 12